Growth hormone research peptides

About growth hormone research peptides

Growth-hormone research peptides divide into two families that are routinely described as interchangeable and are not. GHRH analogues mimic the signal that prompts the pituitary to release growth hormone. Growth-hormone-releasing peptides act on the ghrelin receptor instead, a separate entry point to the same axis.

CJC-1295 is a GHRH analogue and is supplied in two forms. The DAC version carries a drug-affinity complex that extends its half-life substantially; the No DAC version does not. They are different compounds with different research profiles and should not be compared on price alone. Ipamorelin is a GHRP, and is studied alongside GHRH-type compounds rather than in place of them. Tesamorelin is a stabilised GHRH analogue with its own body of published work.

Every vial in this category is supplied lyophilised with a batch-specific certificate of analysis. Where a compound has been reformulated or restocked, the certificate is tied to the released batch rather than to the product line.

All compounds listed are supplied for in vitro laboratory and educational research only. They are not listed on the Australian Register of Therapeutic Goods (ARTG) and are not for human or animal consumption.